AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Clinical Trial Insights on RNA Interference for Rare Diseases
This chapter explores a phase three clinical trial of an RNA interference agent designed to treat ATTR cardiac amyloidosis. It discusses the trial's methodology, including patient demographics, key exclusion criteria, and the outcomes measured over a 12-month period.